Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
615 hedge funds and large institutions have $23.7B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2022 Q4 according to their latest regulatory filings, with 188 funds opening new positions, 130 increasing their positions, 241 reducing their positions, and 95 closing their positions.
393% more funds holding in top 10
Funds holding in top 10: 14 → 69 (+55)
98% more first-time investments, than exits
New positions opened: 188 | Existing positions closed: 95
79% more capital invested
Capital invested by funds: $13.3B → $23.7B (+$10.4B)
16% more funds holding
Funds holding: 530 → 615 (+85)
28% less call options, than puts
Call options by funds: $941M | Put options by funds: $1.3B
46% less repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 241
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HI
HBK Investments
Dallas,
Texas
|
+$380M |
| 2 |
JP Morgan Chase
New York
|
+$371M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$336M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$294M |
| 5 |
SFM
Soros Fund Management
New York
|
+$237M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$675M |
| 2 |
PC
Paulson & Co
New York
|
-$382M |
| 3 |
Barclays
London,
United Kingdom
|
-$257M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$191M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$184M |
HZNP Hedge Fund Activity: Q4 2022 in Review
615 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2022, worth a combined $23.7B — up 79% from $13.3B a quarter earlier.
Buyers outnumbered sellers: 188 funds opened new HZNP positions and 95 closed out — a net gain of 93 holders — while 130 added to existing stakes and 241 trimmed.
The largest buyer was HBK Investments, opening a new position worth an estimated $380M. The largest seller was Janus Henderson Group, cutting an estimated $675M.
- 615 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2022, up from 530 in Q3 2022.
- Funds reported $23.7B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2022, up 79% quarter-over-quarter.
- 188 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2022 and 95 closed out, a net change of +93 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2022 was HBK Investments, an estimated $380M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2022 was Janus Henderson Group, an estimated $675M sold.
Based on aggregated 13F filings for Q4 2022.